Toll样受体在肝衰竭发病中的作用研究进展*

doi:10.3969/j.issn.1672-5069.2014.06.029

摘要/Abstract

摘要： 肝衰竭是多种病因引起的肝功能失代偿,其发病机制涉及肝细胞的坏死、凋亡、再生、肝脏纤维化等。Toll样受体（TLR）作为一种模式识别受体,参与了固有免疫反应和获得性免疫反应,在肝衰竭的发病中起重要作用。动物实验和临床研究均已证实TLR与肝细胞的坏死有关。脂多糖（LPS）、D-氨基半乳糖（D-GalN）、刀豆素A（ConA）、CpG寡脱氧核苷酸（CpG ODN）、多聚肌苷酸-多聚胞苷酸（Poly I:C）和对乙酰氨基酚（APAP）所致的肝损伤需要不同的TLR通路参与。TLR3、TLR4、TLR9参与了肝细胞的凋亡。TLR7对肝纤维化有保护作用。TLR基因多态性研究可以从宿主方面揭示肝衰竭的发病机制,为个体化诊疗提供依据。

关键词: 肝衰竭, Toll样受体, 凋亡

Abstract: Liver failure caused by many etiologies,is a deficiency of liver. Its pathogenesis still remains unclear, and it might involve necrosis,apoptosis and regeneration of the hepatocytes,and fibrosis of the liver. As a kind of pattern recognition receptor,Toll-like receptors（TLRs） link the innate and adaptive immune response,and play an important role in the pathogenesis of liver failure. Animal experiments and clinical studies have demonstrated that TLRs are related to the necrosis of liver cells. Liver injury which is caused by different agents,such as LPS,D-GalN, ConA,CpG ONA,Poly（I:C）and APAP,needs different TLRs signaling. TLR3,TLR4 and TLR9 signaling can promote apoptosis of liver cells. TLR7 signaling has a protective effect against liver fibrosis. Research on TLR polymorphism can reveal the pathogenesis of liver failure from the host aspect, and provide evidences for individualized diagnosis and treatment of patients with liver failure.

Key words: Liver failure, Toll like receptor, Apoptosis

薛源综述, 韩悦, 张欣欣审校. Toll样受体在肝衰竭发病中的作用研究进展^*[J]. 实用肝脏病杂志, 2014, 17(6): 665-669.

Xue Yuan, Han Yue, Zhang Xinxin. Toll-like receptors in pathogenesis of liver failure[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(6): 665-669.

参考文献

[1] 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南（2012年版）. 实用肝脏病杂志,2013,16（3）:210-216.
[2] Kesar V,Odin J A. Toll-like receptors and liver disease. Liver Int,2014,34（2）:184-196.
[3] Ojiro K,Ebinuma H,Nakamoto N,et al. MyD88-dependent pathway accelerates the liver damage of Concanavalin A-induced hepatitis. Biochem Bioph Res Co,2010,36（399）:744-749.
[4] Fisher J E,Mckenzie T J,Lillegard J B,et al. Role of Kupffer cells and toll-like receptor 4 in acetaminophen-induced acute liver failure. J Surg Res,2013,180（1）:147-155.
[5] Chen T,Zhu L,Zhou Y,et al. KCTD9 contributes to liver injury through NK cell activation during hepatitis B virus-induced acute-on-chronic liver failure. Clin Immunol,2013,146（3）:207-216.
[6] Dejager L,Libert C. Tumor necrosis factor alpha mediates the lethal hepatotoxic effects of poly（I:C） in D-galactosamine-sensitized mice. Cytokine,2008,42（1）:55-61.
[7] Shah N,Dhar D,Davies N,et al. Modulation of Toll-like receptor genes with selective gut decontamination in cirrhotic animals prevents the development of acute on chronic liver failure. J Hepatol,2012,24（56）:S225-S388.
[8] Kim S J,Lee S M. NLRP3 inflammasome activation in D-galactosamine and lipopolysaccharide-induced acute liver failure:role of heme oxygenase-1. Free Radic Biol Med,2013,65:997-1004.
[9] Kitazawa T,Tsujimoto T,Kawaratani H,et al. Salvage effect of E5564,Toll-like receptor 4 antagonist on d-galactosamine and lipopolysaccharide-induced acute liver failure in rats. J Gastroenterol Hepatol,2010,25（5）:1009-1012.
[10] Zhu Q,Zou L,Jagavelu K,et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol,2012,56（4）:893-899.
[11] Cavassani K A,Moreira A P,Habiel D,et al. Toll like receptor 3 plays a critical role in the progression and severity of acetaminophen-induced hepatotoxicity. PLoS One,2013,8（6）:e65899.
[12] Shah N,de Montes O M,Jover-Cobos M,et al. Role of toll-like receptor 4 in mediating multiorgan dysfunction in mice with acetaminophen induced acute liver failure. Liver Transpl,2013,19（7）:751-761.
[13] Xing T,Li L,Cao H,et al. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clin Exp Immunol,2007,147（1）:184-188.
[14] Wang K,Liu H,He Y,et al. Correlation of TLR1-10 expression in peripheral blood mononuclear cells with chronic hepatitis B and chronic hepatitis B-related liver failure. Hum Immunol,2010,71（10）:950-956.
[15] Li N,Chen M,Qian Z,et al. Altered monocyte-derived dendritic cells responses to poly（I:C） in patients with acute-on-chronic liver failure. J Hepatol,2012,52:S183-S317.
[16] Li N,Li Q,Qian Z,et al. Impaired TLR3/IFN-beta signaling in monocyte-derived dendritic cells from patients with acute-on-chronic hepatitis B liver failure: relevance to the severity of liver damage. Biochem Biophys Res Commun,2009,390（3）:630-635.
[17] Manakkat Vijay G,Abeles R,Ramage S,et al. Neutrophil intracellular toll like receptor 9 expression severs as a biomarker that determines presence and severity of encephalophathy in acute liver failure and cirrhosis. J Hepatol,2012,56:S103.
[18] Yi A K,Yoon H,Park J E,et al. CpG DNA-mediated induction of acute liver injury in D-galactosamine-sensitized mice:the mitochondrial apoptotic pathway-dependent death of hepatocytes. J Biol Chem,2006,281（21）:15001-15012.
[19] 赵军, 刘旭华,陈煜,等. 内毒素性肝衰竭大鼠TLR4mRNA表达、血清肿瘤坏死因子-α及肝细胞凋亡的动态变化. 胃肠病学和肝脏病学杂志,2008,17（1）:42-45.
[20] Zhang H,Gong Q,Li J H,et al. CpG ODN pretreatment attenuates concanavalin A-induced hepatitis in mice. Int Immunopharmacol,2010,10（1）:79-85.
[21] Wang J,Sun R,Wei H,et al. Poly I:C prevents T cell-mediated hepatitis via an NK-dependent mechanism. J Hepatol,2006,44（3）:446-454.
[22] Yang Q,Shi Y,Yang Y,et al. Deactivation and apoptosis of hepatic macrophages are involved in the development of concanavalin Ainduced acute liver failure. Mol Med Rep,2013, 8（3）:757-762.
[23] Lanford R E,Guerra B,Chavez D,et al. GS-9620,an oral agonist of Toll-like receptor-7,induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology,2013,144（7）:1508-1517.
[24] Marques P E,Amaral S S,Pires D A,et al. Chemokines and mitochondrial products activate neutrophils to amplify organ injury during mouse acute liver failure. Hepatology,2012,56（5）:1971-1982.
[25] Imaeda A B,Watanabe A,Sohail M A,et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest,2009,119（2）:305-314.
[26] Szczeponek A,Sowa J,Schlaak J. Modulation of pro- and anti-regenerative cytokines and transcription factors by TLR stimulation in non-parenchymal liver cells. J Hepatol,2008, 48:S72-S73.
[27] Zorde-Khvalevsky E,Abramovitch R,Barash H,et al. Toll-like receptor 3 signaling attenuates liver regeneration. Hepatology,2009,50（1）:198-206.
[28] Seki E, Tsutsui H,Iimuro Y,et al. Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration. Hepatology,2005,41（3）:443-450.
[29] Moles A,Murphy L,Wilson C L,et al. A TLR2/S100A9/CXCL-2 signaling network is necessary for neutrophil recruitment in acute and chronic liver injury in the mouse. J Hepatol,2013:[Epub ahead of print].
[30] Guo J,Loke J,Zheng F,et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology,2009,49 （3）:960-968.
[31] Roh Y S,Park S,Kim J W,et al. Toll-like receptor 7-mediated Type I Interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis. Hepatology,2013: [Epub ahead of print].
[32] Schott E,Witt H,Neumann K,et al. A Toll-like receptor 7 single nucleotide polymorphism protects from advanced inflammation and fibrosis in male patients with chronic HCV-infection. J Hepatol,2007,47（2）:203-211.
[33] Nischalke H D,Berger C,Aldenhoff K,et al. Toll-like receptor （TLR） 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol,2011,55（5）:1010-1016.
[34] Citores M J,Banos I,Noblejas A,et al. Toll-like receptor 3 L412F polymorphism may protect against acute graft rejection in adult patients undergoing liver transplantation for hepatitis C-related cirrhosis. Transplant Proc,2011,43（6）:2224-2226.
[35] Rong Y,Song H,You S,et al. Association of Toll-like receptor 3 polymorphisms with chronic hepatitis B and hepatitis B-related acute-on-chronic liver failure. Inflammation,2013,36 （2）:413-418.

Toll样受体在肝衰竭发病中的作用研究进展^*

Toll-like receptors in pathogenesis of liver failure

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐飞, 李伟荣. 黄芪甲苷对CCL₄所致肝损伤大鼠的保护作用^*[J]. 实用肝脏病杂志, 2019, 22(6): 808-811.
[2]	廖桂婵, 彭颉, 张小勇. 肝细胞介导的天然免疫应答参与控制乙型肝炎病毒感染^*[J]. 实用肝脏病杂志, 2019, 22(5): 617-619.
[3]	蔡美洪, 王绮夏, 马雄. 肝内胆管缺失的病理生理学研究进展^*[J]. 实用肝脏病杂志, 2019, 22(5): 620-623.
[4]	朱玉成, 闫家微, 孙景坤, 张秋月. 慢加急性肝衰竭患者血清二胺氧化酶水平及其临床意义探讨*[J]. 实用肝脏病杂志, 2019, 22(5): 672-675.
[5]	宋海燕, 陈曦, 张骏飞, 方雪晴, 董静, 陈照林, 潘劲劲, 刘波, 陈从新. 伏立康唑治疗肝衰竭并发肺部真菌感染患者疗效初步研究[J]. 实用肝脏病杂志, 2019, 22(5): 676-679.
[6]	张璇, 唐小云, 唐春银, 石学魁, 王惠琦, 张晓东, 沈海萍, 杨春辉. 中药方剂赤白汤对D-氨基半乳糖诱导的急性肝衰竭小鼠肠道菌群的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 478-481.
[7]	王媛, 党盼玉, 王伟. 血浆置换联合连续性血浆透析滤过治疗慢加急性肝衰竭患者临床疗效及其对血浆细胞因子水平的影响[J]. 实用肝脏病杂志, 2019, 22(4): 541-544.
[8]	彭思璐, 刘冰, 孙宏, 林剑, 潘志颖, 邓存良. HBV相关慢加急性肝衰竭患者预后及其影响因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 545-548.
[9]	钟宋, 刘玉元, 刘树人, 周国柱, 刘崇文, 欧阳石. 慢性乙型肝炎患者肝组织自然杀伤细胞G2D表达水平的变化及其临床意义[J]. 实用肝脏病杂志, 2019, 22(3): 341-344.
[10]	潘劲劲, 董静, 宋海燕, 张俊飞, 陈照林, 刘波. 应用糖皮质激素治疗核苷（酸）类似物撤药性肝炎患者临床疗效评价[J]. 实用肝脏病杂志, 2019, 22(3): 357-360.
[11]	宋芳娇,朱冰,吕飒,田华,王海波,辛绍杰,游绍莉. 314例药物性肝衰竭患者临床特征分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 216-219.
[12]	高朋彬,赵晓彦,秦浩,吴凤影,钟海振,王琳,贾慧娜,李树娟. 戊型肝炎肝衰竭死亡原因分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 220-223.
[13]	张秀灵,段志文,杨瑞东,张晓敏,杨莉,杨海秋,李武. 血源紧张条件下血浆置换联合双重血浆分子吸附系统治疗早中期肝衰竭患者临床研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 289-290.
[14]	范建高. 2018年《实用肝脏病杂志》精彩回顾[J]. 实用肝脏病杂志, 2019, 22(1): 1-3.
[15]	张小三, 张一鸣, 杨树军, 戚春辉, 刘凯, 赵燕. miR-21对HepG2细胞增殖、凋亡和细胞周期的影响^*[J]. 实用肝脏病杂志, 2019, 22(1): 21-24.